CClinicalTrials.gg
RecruitingNCT06976697REACH-tDCSUpdated Aug 14, 2026

Home-Based tDCS Treatment Of Major Depressive Disorder

An interventional study of Transcranial direct current stimulation and Sham transcranial direct current stimulation in Major Depressive Disorder (MDD), sponsored by Sooma Medical Inc. Recruiting at 1 site in United States. Open to participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Sooma Medical Inc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
22 Years to 70 Years
Sex
All
01

Study summary

The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.

Read the detailed description

The study stages include: screening, eligibility evaluation, randomization to active or sham arm (1:1), the first treatment period (weeks 1-10) with sham-control and the optional open-label phase (weeks 11-20) where all treatments will be in active mode.

02

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Depression
  • Brain stimulation
  • Brain
  • Sooma
  • tDCS
  • tES
03

In context

Depressive Disorder, Major

2,741 studies on the registry are indexed under Depressive Disorder, Major; 559 are open to participants now.

This study's planned enrollment of 200 is above the median of 80 across 2,283 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

This is the only study on the registry with Sooma Medical Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

In short,

Inclusion criteria

Inclusion Criteria:

  • 22 - 70 years of age
  • Diagnosis of Unipolar MDD (DSM-V)
  • PHQ-9 score of ≥12 AND MADRS score of ≥ 20 at baseline
  • Antidepressant medication ongoing
  • If in psychotherapy, have maintained stable psychotherapy
  • Have access to a smartphone or other device running Android 7.0+ or iPhone Operating System (iOS) 13+
  • Be under the care of a psychiatrist or a primary care physician
  • Allow communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years
  • Provide the name and contact of at least two adult persons who reside within a 60-minute drive of the patient's residence.
  • Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
  • Be willing and able to comply with all study procedures
  • Agree to meet all of the inclusion criteria throughout their participation in the study. Otherwise, the subject will be discontinued from the study
  • Be able to understand, speak, and read English sufficient for the completion of trial assessments

Exclusion criteria

Exclusion Criteria:

  • Current state of mania or psychosis, or have a history of mania or psychosis.
  • Treatment resistant depression.
  • Are diagnosed with vitamin or hormonal deficiencies that may mimic mood disorders, as determined by the investigator.
  • Be currently receiving any other interventional therapy for MDD other than a stable regimen of antidepressants or psychotherapy as defined in the inclusion criteria or have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation.
  • Have moderate or greater suicidality risk, or an attempt of suicide during lifetime or any previous hospitalization for suicidal behavior.
  • Diagnosis of sleep apnea with prescribed treatment (unless they are on CPAP treatment and are compliant with treatment) or a diagnosis of insomnia that is unrelated to depression, as determined by the investigator.
  • Have any structural lesion or any neurocranial defect or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results, as determined by the investigator.
  • Have any implant in the brain (e.g., DBS) or neurocranium, or any other active implantable medical device anywhere in the body (e.g. pacemaker, insulin pump).
  • Have a history of epilepsy or seizures.
  • Have shrapnel or any ferromagnetic material in the head.
  • Have any disorder that would impair the ability to complete the study questionnaires.
  • Have been diagnosed with autism spectrum disorder.
  • Have an alcohol use disorder or substance use disorder (past 12 months).
  • Have a cognitive impairment (including dementia).
  • medications that affect cortical excitability, as determined by the investigator.
  • Have ever taken esketamine / ketamine for treatment of depression.
  • Are currently admitted or have ever been admitted to a dedicated psychiatric ward for depression for a period of more than 24 hours.
  • Have ever been diagnosed with obsessive-compulsive disorder (OCD) or bipolar type 1 or 2 disorder.
  • Be diagnosed with PTSD, agoraphobia, anorexia or bulimia, panic or personality disorder, with active symptoms, based on the investigator's judgment.
  • Have any history of myocardial infarction, coronary artery bypass graft (CABG), coronary heart failure (CHF), or history of other cardiac issues.
  • Be currently experiencing or have a history of intractable migraines.
  • Be a chronic nicotine user.
  • Be currently pregnant or breastfeeding or planning to become pregnant or breastfeed any time during the study, or lack a medically acceptable method of contraception in females with child-bearing potential.
  • Be currently incarcerated.
  • Be participating concurrently in another clinical investigation or have participated in a clinical investigation within the last 90 days or intend to participate in another clinical investigation during the study.
  • Have a hairstyle or hair type, such as very thick hair or voluminous hairstyle, that would prevent wearing of the treatment cap tightly enough on the head that the electrodes are held close to the scalp.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Active treatment

    Device: Transcranial direct current stimulation

  • Sham comparator
    Sham treatment

    Device: Sham transcranial direct current stimulation

Interventions

  • DeviceTranscranial direct current stimulation

    In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.

  • DeviceSham transcranial direct current stimulation

    Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.

06

What researchers measure

Primary outcomes

  1. MADRS: change from baseline

    Mean change in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score, from baseline to week 10. MADRS ranges from 0 to 60, with higher scores indicating more severe depression.

    Time frame: 10 weeks from treatment initiation.

Secondary outcomes

  1. MADRS: rate of response

    Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their MADRS at week 10.

    Time frame: 10 weeks from treatment initiation.

  2. MADRS: rate of remission

    Rate of remission remission defined as the percent of subjects with MADRS score ≤ 10 at week 10.

    Time frame: 10 weeks from treatment initiation.

  3. HAM-D17: change form baseline

    Mean change in depressive symptoms, measured by Hamilton Depression Rating Scale (17-items) (HAM-D17), from baseline to week 10. HAM-D17 ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: 10 weeks from treatment initiation.

  4. HAM-D17: rate of response

    Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their HAM-D17 at week 10.

    Time frame: 10 weeks from treatment initiation.

  5. HAM-D17: rate of remission

    Rate of remission defined as the percent of subjects with HAM-D17 score ≤ 7 at week 10.

    Time frame: 10 weeks from treatment initiation.

  6. PHQ-9: change from baseline

    Mean change in depressive symptoms, measured by Patient Health Questionnaire-9 (PHQ-9) total score, from baseline to week 10. PHQ-9 ranges from 0 to 27, with higher scores indicating more severe depression.

    Time frame: 10 weeks from treatment initiation.

  7. PHQ-9: rate of response

    Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their PHQ-9 at week 10.

    Time frame: 10 weeks from treatment initiation.

  8. PHQ-9: rate of remission

    Rate of remission, defined as the percent of subjects with PHQ-9 score ≤ 4 at week 10.

    Time frame: 10 weeks from treatment initiation.

  9. CGI-I

    The clinical global impression - improvement scale (CGI-I) is a 7-point scale allowing the clinical rater to assess how much the patient's overall condition has improved or worsened since starting the intervention (1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse).

    Time frame: 10 weeks from treatment initiation.

07

Study locations

1 of 1 sites recruiting
  • Curavit Clinical Research (virtual study site)
    Boston, Massachusetts 02116, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The IPD used in the results of the publication will be shared.

Supporting information: Study protocol, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976697
Lead sponsor
Sooma Medical Inc
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jun 27, 2025
Primary completion
Oct 10, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
Aug 14, 2026

Study contacts

Christopher Reist, M.D.
principal investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion